PCT. On- Time Points 97% + 20 points 95%-96% 19 points 93%-94% 18 points 91%-92% 17 points 89%-90% 16 points 87%-88% 15 points < 87% 14 points
PCT. Range of Principal of Principal Avg. Avg. Full Original LTV Count Balance Total Balance Coupon CLTV Doc ------------ ----- ------- ----- ------- ------ ---- --- 5.01 - 10.00 47 842,659.38 0.13 17,928.92 12.57 60.28 78.05 10.01 - 15.00 256 5,912,208.50 0.88 23,094.56 12.11 71.51 84.91 15.01 - 20.00 358 9,087,933.27 1.36 25,385.29 12.13 70.31 84.94 20.01 - 25.00 300 8,997,068.81 1.34 29,990.23 11.96 64.94 77.03 25.01 - 30.00 290 9,768,655.70 1.46 33,685.02 11.89 62.3 83.71 30.01 - 35.00 224 7,673,279.80 1.15 34,255.71 11.78 57.88 79.87 35.01 - 40.00 253 9,858,327.06 1.47 38,965.72 12.01 55.31 77.82 40.01 - 45.00 215 8,946,027.42 1.34 41,609.43 11.73 51.81 78.85 45.01 - 50.00 437 16,990,336.67 2.54 38,879.49 12.54 51.1 67.18 50.01 - 55.00 297 14,014,587.98 2.09 47,187.16 11.82 54.44 72.78 55.01 - 60.00 515 22,855,426.84 3.42 44,379.47 11.9 59.41 70 60.01 - 65.00 674 37,847,230.64 5.66 56,153.16 12.09 63.87 65.76 65.01 - 70.00 973 56,486,817.09 8.44 58,054.28 11.82 69.12 71.19 70.01 - 75.00 1,300 82,887,084.45 12.39 63,759.30 11.56 74.23 77.72 75.01 - 80.00 2,499 168,244,615.24 25.15 67,324.78 11.33 79.51 92.43 80.01 greater than = 2,457 208,659,722.91 31.19 84,924.59 11.25 86.72 98.2 ----- ----- -------------- ----- --------- ----- ----- ---- Total: 11,095 669,071,981.76 100 60,303.92 11.54 75.77 86.22 ====== ============== === ========= ===== ===== ===== Min: 6.90 Max: 100.00 Weighted Average: 72.55
PCT. Uranium was determined using a neutron activation method with delayed neutron counting. A detailed description of the method is provided by Boulanger et al. (1975). In brief, a 1 gram sample is weighed into a 7 dram polyethylene vial, capped and sealed. The irradiation is provided by the Slowpoke reactor with an operating flux of 10** 12 neutrons/sq cm/sec. The samples are pneumatically transferred from an automatic loader to the reactor, where each sample is irradiated for 60 seconds. After irradiation, the sample is again transferred pneumatically to the counting facility where after a 10 second delay the sample is counted for 60 seconds with six BF 3 detector tubes embedded in paraffin. Following counting, the samples are automatically ejected into a shielded storage container. Calibration is carried out twice a day as a minimum, using natural materials of known uranium concentration. Detection limit = 0.5 ppm. Xxxxxxxx was determined as described by Xxxxx (1976). A 500 mg sample is placed in a test tube; 3 mL concentrated HNO3 and 9 mL concentrated HCl are added and the mixture is allowed to stand overnight at room temperature. The mixture is heated slowly to 90 ° C and maintained at this temperature for at least 90 minutes. The solution is cooled and diluted to 10 mL with 1 . 8 M HCl. The antimony in an aliquot of this dilute solution is then determined by hydride evolution - atomic absorption spectrometry. Detection limit = 0.2 ppm. Xxxxxxxx was determined as described by Xxxxxxx (1970). A 250 mg sample is sintered with 1 g of a flux consisting of two parts by weight sodium carbonate and one part by weight potassium nitrate. The residue is then leached with water. The sodium carbonate is neutralized with 10 mL 10% (w/v) citric acid and the resulting solution is diluted to 100 mL with water. The pH of the resulting solution should be from 5 . 5 to 6 . 5 . The fluoride content of the test solution is then measured using a f luoride ion electrode. Standard solutions contain sodium carbonate and citric acid in the same quantities as the sample solution. Detection limit = 20 ppm. Gold was usually determined on a 10 g sediment sample; depending on the amount of sample available, lesser weights were sometimes used. This resulted in a variable detection limit: 2 ppb for a 5 g sample, 1 ppb for a 10 g sample... The sample was fused to produce a lead button, collecting any gold in the sample, which was cupelled in a muffle furnace to produce a silver (dore) be...
PCT. QUALITY OF OIL SHOULD COINCIDE WITH THE EXISTING NORMS. SELLER AND BUYER SHALL MEET TO AGREE THE APPOINTMENT OF AN INDEPENDENT EXPERT LABORATORY, TO WHOM ANY DISPUTES CONCERNING THE QUALITY OF THE OIL OR THE METHOD OF TESTING THEREOF SHALL BE REFERRED AND BOTH PARTIES MUST ACCEPT THE DECISION OF THE EXPERT.
PCT. PCT is a wholly-owned subsidiary of the Company established in Greece. PCT is principally engaged in the businesses of operating Pier 2 and Pier 3, including general cargo and container terminals and related operations.
PCT. Range of Principal of Principal Avg. Avg. Full Margins Count Balance Total Balance Coupon CLTV Doc --------------- ----- ------------- ----- ---------- ------ ----- ----- 0.00 - 3.99 10 1,473,802.59 0.61 147,380.26 9.27 80.49 64.42 4.00 - 4.99 86 9,626,117.65 3.96 111,931.60 9 76.58 89.86 5.00 - 5.99 700 71,159,741.41 29.31 101,656.77 9.39 76.55 84.39 6.00 - 6.99 1,045 85,097,755.46 35.05 81,433.26 10.14 76 82.64 7.00 - 7.99 798 54,367,025.07 22.39 68,129.10 10.87 73.48 81.4 8.00 - 8.99 319 17,713,584.82 7.3 55,528.48 11.79 70.31 78.45 9.00 - 9.99 59 3,290,676.97 1.36 55,774.19 12.87 67.69 70.74 10.00 - 10.99 3 75,113.13 0.03 25,037.71 14.19 55.81 72.85 ----- -------------- ----- ---------- ----- ----- ----- Total: 3,020 242,803,817.10 100 80,398.61 10.19 75.11 82.58 ===== ============== ===== ========== ===== ===== ===== Min: 0.000 Max: 10.750 Weighted Average: 6.510 -------------------------------------------------------------------------------- NOTE: Percentages may not add to 100.00% due to rounding. The above analysis is not intended to be a prospectus and any investment decision with respect to the security should be made by you based solely upon all of the information contained in the final prospectus. Under no circumstances shall the information presented constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities may not be sold nor may an offer to buy be accepted prior to the delivery of a final prospectus relating to the securities. The above preliminary description of the underlying assets has been provided by the issuer and has not been independently verified by Credit Suisse First Boston. All information described above is preliminary, limited in nature and subject to completion or amendment. Credit Suisse First Boston makes no representations that the above referenced security will actually perform as described in any scenario presented. [GRAPHIC OMITTED] -------------------------------------------------------------------------------- ContiMortgage Home Equity Loan Trust 1997-3 ARM -------------------------------------------------------------------------------------------------------------------------------- Initial Outstanding Pct. Average Wtd. Wtd. Pct. Periodic Principal of Principal Avg. Avg. Full Cap Count...
PCT. Range of Principal of Principal Avg. Avg. Full Seasoning Count Balance Total Balance Coupon CLTV Doc --------- ----- ------- ----- ------- ------ ---- --- 0 - 1 1,813 146,025,742.31 60.14 80,543.71 10.14 74.97 82.08 2 - 12 1,207 96,778,074.79 39.86 80,180.68 10.27 75.33 83.34 ----- ------------- ----- --------- ----- ----- ----- Total: 3,020 242,803,817.10 100 80,398.61 10.19 75.11 82.58 ===== ============== === ========= ===== ===== ===== Min: 0 Max: 10 Weighted Average: 1.34 -------------------------------------------------------------------------------- NOTE: Percentages may not add to 100.00% due to rounding. The above analysis is not intended to be a prospectus and any investment decision with respect to the security should be made by you based solely upon all of the information contained in the final prospectus. Under no circumstances shall the information presented constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities may not be sold nor may an offer to buy be accepted prior to the delivery of a final prospectus relating to the securities. The above preliminary description of the underlying assets has been provided by the issuer and has not been independently verified by Credit Suisse First Boston. All information described above is preliminary, limited in nature and subject to completion or amendment. Credit Suisse First Boston makes no representations that the above referenced security will actually perform as described in any scenario presented. [GRAPHIC OMITTED] --------------------------------------------------------------------------------
PCT. (M) Watchmen’s duties also include, but are not limited to: Security work performed by watchmen shall not be assigned to others.
PCT. The Contractor shall work in collaboration with ORDC to establish and participate on a PCT (Project Coordination Team) that shall consist of monthly meetings unless otherwise requested by the Government, which shall include the Contractor’s participation and may include multiple organizations within the Department of Health & Human Services. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Contract Number HHSO100200500006C Modification 1, page 6 of 11 HGS, Inc. Usable Product: FDP produced from or following three consistency lots shall be used in animal and clinical studies and shall be the product delivered to the SNS after completion of all necessary studies to fulfill the “usable product” requirement of the contract. Three conformance lots shall be produced prior to BLA application. If there is a difference in conformance lots compared to the earlier consistency lots, the Contractor shall replace the product that is in the SNS with the new product at no cost to the Government.
PCT. Co-owned between Exogen, Inc. and inventors.
